Elsevier brief: need for evidence-based medicine is urgent

| | Health Exec | Precision Medicine

An Elsevier news brief is stressing the need for a business case for evidence-based medicine (EBM) to improve the U.S. healthcare system. The brief culminated from a roundtable discussion of healthcare industry thought leaders at the CMIO Leadership Forum in Chicago last fall.

EBM is a learning process that involves: the conversion of information needs into focused questions; identification of the best evidence for answering a question; review of evidence for validity and clinical usefulness; application of results to clinical practice; and evaluation of how the evidence performs in clinical applications.

To read more about the opportunities and strategies to move EMB forward, check out the brief below:

Building a Business Case for Evidence-Based Medicine

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.